Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice

Infection and Immunity

Volumn 67, Issue 11, 1999, Pages 6191-6193

  Konadu, Edward ^a   Donohue Rolfe, Arthur ^b   Calderwood, Stephen B ^c   Pozsgay, Vince ^a   Shiloach, Joseph ^d   Robbins, John B ^a   Szu, Shousun C ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b TUFTS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; SHIGA TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; ESCHERICHIA COLI O157; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032708674     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.11.6191-6193.1999     Document Type: Article

References (29)

1. Acheson, D. W. K., S. B. Calderwood, S. A. Boyko, L. L. Lincicome, A. V. Kane, A. Donohue-Rolfe, and G. T. Keusch. 1993. Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systems. Infect. Immun. 61:1098-1104.
2. Acheson, D. W. K., M. M. Levlne, J. B. Kaper, and G. T. Keusch. 1996. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:355-357.
3. Austin, P., and C. J. Hovde. 1995. Purification of recombinant shiga-like toxin type I B subunit. Protein Expr. Purif. 6:771-779.
4. Barington, T., A. Gyhrs, K. Kristensen, and C. Heilmann. 1994. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect. Immun. 62:9-14.
5. Bell, B. P., P. M. Griffin, P. Lozano, L. Christie, J. M. Kobayashi, and P. I. Tarr. 1997. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:12.
6. Bitzan, M., H. Karch, H. Altrogge, J. Strehlau, and F. Blaker. 1988. Hemolytic uremic syndrome associated with a variant shiga-like cytotoxin of Escherichia coli O111. Pediatr. Infect. Dis. J. 7:128-132.
7. Caprioli, A., I. Luzzi, and F. Rosmini. 1994. Community wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. J. Infect. Dis. 169:208-211.
8. Cohen, D., S. Ashkenazi, M. S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D. N. Taylor, T. L. Hale, J. C. Sadoff, D. Pavliakova, R. Schneerson, and J. B. Robbins. 1997. Protection against shigellosis conferred by an investigational Shigella sonnei conjugate vaccine in adults. Lancet 349:155-159.
9. Gentry, M., and J. M. Dalrymple. 1980. Quantitative microtiter cytotoxicity assay for Shigella toxin. J. Clin. Microbiol. 12:361-366.
10. Huppertz, H., D. Busch, H. Schmidt, S. Aleksic, and H. Karch. 1996. Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. J. Pediatr. 128:341-346.
11. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, G. S. Arbus, and H. Lior. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782.
12. Konadu, E., J. B. Robbins, J. Shiloach, D. A. Bryla, and S. C. Szu. 1994. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 62:5048-5054.
13. Konadu, E., J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1996. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid, with emphasis on the role of O acetyls. Infect. Immun. 64:2709-2715.
14. Konadu, E. Y., J. C. Park, Jr., H. T. Tran, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1998. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugates in adults. J. Infect. Dis. 177:383-387.
15. Lees, A., B. Nelson, and J. J. Mond. 1995. Activation of soluble polysaccharide with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
16. Neill, M. A., P. L. Tarr, C. R. Clausen, D. L. Christie, and R. O. Hickman. 1987. Escherichia coli O157:H7 and the predominant pathogen associated with hemolytic uremic syndrome: a prospective study in the Pacific Northwest. Pediatrics 80:37-40.
17. O'Brien, A. D., and G. D. LaVeck. 1983. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect. Immun. 40:675-683.
18. Ohmura, M., S. Yamasaki, H. Kurazono, K. Kashiwagi, K. Igarashi, and Y. Takeda. 1993. Characterization of non-toxic mutant toxins of Vero toxin 1 that were constructed by replacing amino acids in the A subunit. Microb. Pathog. 15:169-176.
19. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in E. coli O157:H7 infections. J. Infect. Dis. 160:994-998.
20. Perry, M. B., D. R. Bundle, L. MacLean, J. A. Perry, and D. W. Griffith. 1986. The structure of the antigenic lipopolysaccharide O-chains produced by Salmonella urbana and Salmonella godesberg. Carbohydr. Res. 156:107-122.
21. Pozsgay, V., L. Trinh, J. Shiloach, J. B. Robbins, A. Donohue-Rolfe, and S. B. Calderwood. 1996. Purification of subunit B of Shiga toxin using a synthetic trisaccharide-based affinity matrix. Bioconjug. Chem. 7:45-55.
22. Proulx, F., J. P. Turgeon, G. Delage, L. Lafleur, and L. Chicoine. 1992. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J. Pediatr. 121:299-303.
23. Riley, L. W., R. S. Remis, S. D. Helgerson, H. B. McGee, J. G. Wells, B. R. Davis, R. J. Hebert, E. S. Olcolt, L. M. Johnson, N. T. Hargrett, P. A. Blake, and M. L. Cohen. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685.
24. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
25. Scotland, S. M., G. A. Willshaw, H. R. Smith, and B. Rowe. 1987. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 99:613-624.
26. Slutsker, L., A. A. Ries, K. Maloney, J. G. Wells, K. D. Greene, P. M. Griffin, and The Escherickia coli O157:H7 Study Group. 1998. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J. Infect. Dis. 177:962-966.
27. Szu, S. C., X. Li, R. Schneerson, J. Vickers, and J. B. Robbins. 1989. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun. 57:3823-3827.
28. Tarr, P. I., and M. A. Neill. 1996. Perspective: the problem of non-O157:H7 shiga toxin (verocytotoxin)-producing Escherichia coli. J. Infect. Dis. 174: 1136-1139.
29. Weinstein, D. L., M. P. Jackson, L. P. Perera, R. K. Holmes, and A. D. O'Brien. 1989. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity. Infect. Immun. 57:3743-3750.